FDA Approves First Oral Antiviral for COVID-19 Prevention

The U.S. Food and Drug Administration (FDA) has granted approval for the oral antiviral medication ensitrelvir, known as Xocova, for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older. Announced around October 19, 2026, this approval represents a significant development in the fight against COVID-19, introducing the first and only oral option available in the United States for preventing symptomatic COVID-19 after exposure. This new therapeutic option addresses a crucial need in the current landscape of COVID-19 prevention.

Ensitrelvir functions as a main protease inhibitor that targets the SARS-CoV-2 virus, responsible for COVID-19. By inhibiting the main protease enzyme essential for viral replication, ensitrelvir effectively suppresses the virus's ability to reproduce. The treatment regimen consists of a 5-day course, with three tablets taken on the first day and one tablet taken on each subsequent day. This straightforward administration enhances accessibility for individuals who may be at risk of developing COVID-19 after exposure.

The approval of ensitrelvir followed the results of the Phase 3 SCORPIO-PEP trial, a randomized, double-blind, placebo-controlled study that evaluated the drug's efficacy and safety among household contacts of individuals with symptomatic COVID-19. The trial demonstrated a significantly lower incidence of COVID-19 in participants receiving ensitrelvir compared to those receiving a placebo, showcasing its potential effectiveness in real-world scenarios. The findings from this trial were published in The New England Journal of Medicine.

Ensitrelvir's approval is expected to bring substantial benefits to public health efforts aimed at controlling COVID-19. By providing a proactive measure for those exposed to the virus, it offers an additional layer of protection, particularly in high-risk environments such as nursing homes and healthcare facilities. This oral antiviral could play a vital role in reducing the spread of COVID-19 and protecting vulnerable populations from severe illness.

Looking forward, the introduction of ensitrelvir marks a promising step in the ongoing battle against COVID-19. As the pandemic continues to evolve, having effective preventive options will be key in managing the spread of the virus. The FDA's approval of ensitrelvir not only enhances the arsenal of available treatments but also reinforces the importance of research and innovation in addressing public health challenges related to COVID-19.